Updated clinical experience with MACOP-B

Paul Klimo, Joseph M. Connors

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

This paper summarizes our experience with MACOP-B chemotherapy (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) in 125 patients with advanced stage, diffuse, large cell non-Hodgkin's lymphoma referred to the Cancer Control Agency of British Columbia between April 1981 and June 1986. Complete response (CR) was achieved in 105 patients (84%), partial response (PR) in 18 patients (14.4%) and primary treatment failure occurred in two patients (1.6%). Fifteen of the PRs and both nonresponders succumbed to their disease. Of the 105 CRs, 23 patients (21%) suffered a relapse; 14 of the relapsers eventually died from their lymphoma, five are in second CR, three are receiving further therapy, and one has histologic evidence of asymptomatic, low-grade lymphoma. Three deaths were unrelated to lymphoma. Overall toxicity was acceptable, with only six treatment-related deaths (4.8%). The incidence of nonfatal systemic proven or suspected infections was 10%. Mucocutaneous side effects remain the most frequent toxicity of the MACOP-B protocol. More than half of the 125 patients received at least a portion of MACOP-B from community oncologists. The results of treatment with MACOP-B remain at least comparable to the best reported in the literature, yet they have been achieved with less toxicity, over shorter periods of time, and with diminished socioeconomic impact on patients. However, improvement on these results is necessary both in terms of efficacy and toxicity. A new variant of MACOP-B is now being tested and our preliminary experience has been encouraging.

Original languageEnglish (US)
Pages (from-to)26-34
Number of pages9
JournalSeminars in Hematology
Volume24
Issue number2 SUPPL. 1
StatePublished - Apr 1 1987
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
British Columbia
Vincristine
Prednisone
Treatment Failure
Methotrexate
Doxorubicin
Cyclophosphamide
Therapeutics
Recurrence
Drug Therapy
Incidence
Infection
Neoplasms
Oncologists
MACOP-B protocol
indium-bleomycin

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Klimo, P., & Connors, J. M. (1987). Updated clinical experience with MACOP-B. Seminars in Hematology, 24(2 SUPPL. 1), 26-34.

Updated clinical experience with MACOP-B. / Klimo, Paul; Connors, Joseph M.

In: Seminars in Hematology, Vol. 24, No. 2 SUPPL. 1, 01.04.1987, p. 26-34.

Research output: Contribution to journalArticle

Klimo, P & Connors, JM 1987, 'Updated clinical experience with MACOP-B', Seminars in Hematology, vol. 24, no. 2 SUPPL. 1, pp. 26-34.
Klimo P, Connors JM. Updated clinical experience with MACOP-B. Seminars in Hematology. 1987 Apr 1;24(2 SUPPL. 1):26-34.
Klimo, Paul ; Connors, Joseph M. / Updated clinical experience with MACOP-B. In: Seminars in Hematology. 1987 ; Vol. 24, No. 2 SUPPL. 1. pp. 26-34.
@article{fe144fe156044dfb9aad3d4b3c8ffd0b,
title = "Updated clinical experience with MACOP-B",
abstract = "This paper summarizes our experience with MACOP-B chemotherapy (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) in 125 patients with advanced stage, diffuse, large cell non-Hodgkin's lymphoma referred to the Cancer Control Agency of British Columbia between April 1981 and June 1986. Complete response (CR) was achieved in 105 patients (84{\%}), partial response (PR) in 18 patients (14.4{\%}) and primary treatment failure occurred in two patients (1.6{\%}). Fifteen of the PRs and both nonresponders succumbed to their disease. Of the 105 CRs, 23 patients (21{\%}) suffered a relapse; 14 of the relapsers eventually died from their lymphoma, five are in second CR, three are receiving further therapy, and one has histologic evidence of asymptomatic, low-grade lymphoma. Three deaths were unrelated to lymphoma. Overall toxicity was acceptable, with only six treatment-related deaths (4.8{\%}). The incidence of nonfatal systemic proven or suspected infections was 10{\%}. Mucocutaneous side effects remain the most frequent toxicity of the MACOP-B protocol. More than half of the 125 patients received at least a portion of MACOP-B from community oncologists. The results of treatment with MACOP-B remain at least comparable to the best reported in the literature, yet they have been achieved with less toxicity, over shorter periods of time, and with diminished socioeconomic impact on patients. However, improvement on these results is necessary both in terms of efficacy and toxicity. A new variant of MACOP-B is now being tested and our preliminary experience has been encouraging.",
author = "Paul Klimo and Connors, {Joseph M.}",
year = "1987",
month = "4",
day = "1",
language = "English (US)",
volume = "24",
pages = "26--34",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Updated clinical experience with MACOP-B

AU - Klimo, Paul

AU - Connors, Joseph M.

PY - 1987/4/1

Y1 - 1987/4/1

N2 - This paper summarizes our experience with MACOP-B chemotherapy (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) in 125 patients with advanced stage, diffuse, large cell non-Hodgkin's lymphoma referred to the Cancer Control Agency of British Columbia between April 1981 and June 1986. Complete response (CR) was achieved in 105 patients (84%), partial response (PR) in 18 patients (14.4%) and primary treatment failure occurred in two patients (1.6%). Fifteen of the PRs and both nonresponders succumbed to their disease. Of the 105 CRs, 23 patients (21%) suffered a relapse; 14 of the relapsers eventually died from their lymphoma, five are in second CR, three are receiving further therapy, and one has histologic evidence of asymptomatic, low-grade lymphoma. Three deaths were unrelated to lymphoma. Overall toxicity was acceptable, with only six treatment-related deaths (4.8%). The incidence of nonfatal systemic proven or suspected infections was 10%. Mucocutaneous side effects remain the most frequent toxicity of the MACOP-B protocol. More than half of the 125 patients received at least a portion of MACOP-B from community oncologists. The results of treatment with MACOP-B remain at least comparable to the best reported in the literature, yet they have been achieved with less toxicity, over shorter periods of time, and with diminished socioeconomic impact on patients. However, improvement on these results is necessary both in terms of efficacy and toxicity. A new variant of MACOP-B is now being tested and our preliminary experience has been encouraging.

AB - This paper summarizes our experience with MACOP-B chemotherapy (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) in 125 patients with advanced stage, diffuse, large cell non-Hodgkin's lymphoma referred to the Cancer Control Agency of British Columbia between April 1981 and June 1986. Complete response (CR) was achieved in 105 patients (84%), partial response (PR) in 18 patients (14.4%) and primary treatment failure occurred in two patients (1.6%). Fifteen of the PRs and both nonresponders succumbed to their disease. Of the 105 CRs, 23 patients (21%) suffered a relapse; 14 of the relapsers eventually died from their lymphoma, five are in second CR, three are receiving further therapy, and one has histologic evidence of asymptomatic, low-grade lymphoma. Three deaths were unrelated to lymphoma. Overall toxicity was acceptable, with only six treatment-related deaths (4.8%). The incidence of nonfatal systemic proven or suspected infections was 10%. Mucocutaneous side effects remain the most frequent toxicity of the MACOP-B protocol. More than half of the 125 patients received at least a portion of MACOP-B from community oncologists. The results of treatment with MACOP-B remain at least comparable to the best reported in the literature, yet they have been achieved with less toxicity, over shorter periods of time, and with diminished socioeconomic impact on patients. However, improvement on these results is necessary both in terms of efficacy and toxicity. A new variant of MACOP-B is now being tested and our preliminary experience has been encouraging.

UR - http://www.scopus.com/inward/record.url?scp=0023319265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023319265&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 26

EP - 34

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2 SUPPL. 1

ER -